Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects

被引:16
作者
Cartolano, Flavia De C. [1 ]
Dias, Gabriela D. [1 ]
de Freitas, Maria C. P. [1 ]
Figueiredo Neto, Antonio M. [2 ]
Damasceno, Nagila R. T. [1 ]
机构
[1] Univ Sao Paulo, Sch Publ Hlth, Dept Nutr, Sao Paulo, SP, Brazil
[2] Univ Sao Paulo, Inst Phys, Dept Expt Phys, Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
HOMEOSTASIS MODEL ASSESSMENT; GLUCOSE CLAMP TECHNIQUE; CORONARY-HEART-DISEASE; PLASMA; DYSLIPIDEMIA; OBESITY; HDL; HYPERTRIGLYCERIDEMIA; HYPERINSULINEMIA; PATHOPHYSIOLOGY;
D O I
10.1155/2017/1018796
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Atherogenic diabetes is associated with an increased cardiovascular risk and mortality in diabetic individuals; however, the impact of insulin resistance (IR) in lipid metabolism in preclinical stages is generally underreported. For that, we evaluated the capacity of IR to predict an atherogenic lipid subfraction profile. Methods. Complete clinical evaluation and biochemical analysis (lipid, glucose profile, LDL, and HDL subfractions and LDL phenotype and size) were performed in 181 patients. The impact of IR as a predictor of atherogenic lipoproteins was tested by logistic regression analysis in raw and adjusted models. Results. HDL-C and Apo AI were significantly lower in individuals with IR. Individuals with IR had a higher percentage of small HDL particles, lower percentage in the larger ones, and reduced frequency of phenotype A (IR = 62%; non-IR = 83%). IR individuals had reduced probability to have large HDL (OR = 0.213; CI = 0.999-0.457) and had twice more chances to show increased small HDL (OR = 2.486; CI = 1.341-7.051). IR was a significant predictor of small LDL (OR = 3.075; CI = 1.341-7.051) and atherogenic phenotype (OR = 3.176; CI = 1.469-6.867). Conclusion. IR, previously DM2 diagnosis, is a strong predictor of quantitative and qualitative features of lipoproteins directly associated with an increased atherogenic risk.
引用
收藏
页数:8
相关论文
共 47 条
[1]   Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) :1225-1236
[2]  
[Anonymous], 2016, Diabetes and Cardiovascular Disease
[3]   Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis [J].
Arca, Marcello ;
Pigna, Giovanni ;
Favoccia, Carla .
CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (06) :684-686
[4]   Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men [J].
Banerji, MA ;
Faridi, N ;
Atluri, R ;
Chaiken, RL ;
Lebovitz, HE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :137-144
[5]   New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease [J].
Barter P.J. ;
Puranik R. ;
Rye K.-A. .
Current Cardiology Reports, 2007, 9 (6) :493-498
[6]   Metabolic origins and clinical significance of LDL heterogeneity [J].
Berneis, KK ;
Krauss, RM .
JOURNAL OF LIPID RESEARCH, 2002, 43 (09) :1363-1379
[7]   Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[8]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[9]  
DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
[10]   The composition and metabolism of large and small LDL [J].
Diffenderfer, Margaret R. ;
Schaefer, Ernst J. .
CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (03) :221-226